|
Early Bird ending: 2 days left to save — JPM26 in SF + online Jan 12-13 No images? Click here 
Behind the $10 billion bets being placed todayJANUARY 12 - 13, 2026 | 7:00 AM - 5:00 PM PT Early Bird rate ends in 2 daysThe contradictions continue: while biotech stocks struggle and funding remains scarce, M&A just delivered multiple $10 billion-plus acquisitions. At Endpoints at JPM, the dealmakers behind these transactions are ready to explain what drove them to bet big while others sat on the sidelines — and what they see coming next. Does this M&A surge signal a broader recovery or just deep-pocketed buyers cherry-picking assets while valuations stay depressed? Join us for sessions that deliver unfiltered perspectives when the industry needs them most. Early Bird ends on December 4:
SPOTLIGHT PANELThe view from China China’s leading drug developer Jiangsu Hengrui Pharmaceuticals has spent the past year doing deals with US and European companies. We’ll talk with Chief Strategy Officer Frank Jiang about how the company is thinking about its role on the global stage. 
Frank Jiang Endpoints at JPM26 exclusive data: What biopharma leaders really think about 2026We're unveiling exclusive data from our new Biopharma Sentiment Index (BPSI), drawn from Endpoints readers who sit at the center of industry decision-making. What do executives actually think when surveyed anonymously about funding trajectories, regulatory challenges, and which therapeutic areas will attract capital? You'll get the real picture on where dealmakers are focused and where leaders expect continued pain. Plus, the Endpoints Hub offers a premium coworking lounge, a place to escape the noise, compare notes with peers who get it, and figure out your next move over breakfast, lunch, and real conversation. These conversations will set your agenda for navigating what's ahead. Join us. Save with Early Bird in-person tickets: Ends 12/4 at midnightCan't make it to SF? Virtual passes are available at no charge EVENT SPONSORS 
|
